Ownership Capital B.V. Sells 162,860 Shares of DexCom, Inc. (NASDAQ:DXCM)

Ownership Capital B.V. cut its position in DexCom, Inc. (NASDAQ:DXCM) by 17.6% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 761,810 shares of the medical device company’s stock after selling 162,860 shares during the quarter. DexCom makes up approximately 1.6% of Ownership Capital B.V.’s investment portfolio, making the stock its 21st largest holding. Ownership Capital B.V.’s holdings in DexCom were worth $51,072,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Vanguard Group Inc. increased its stake in shares of DexCom by 0.3% in the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after purchasing an additional 136,282 shares during the period. Blair William & Co. IL grew its holdings in DexCom by 1.4% in the 1st quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock valued at $628,684,000 after buying an additional 64,683 shares during the last quarter. Legal & General Group Plc increased its position in DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after buying an additional 49,076 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after buying an additional 353,019 shares during the last quarter. Finally, 1832 Asset Management L.P. boosted its position in shares of DexCom by 1.1% in the first quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock valued at $252,906,000 after acquiring an additional 20,400 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on DXCM. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. Royal Bank of Canada cut their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Piper Sandler reissued an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Raymond James lowered their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Finally, Wells Fargo & Company raised their price objective on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

DexCom Price Performance

NASDAQ:DXCM opened at $69.96 on Friday. The firm has a market cap of $27.33 billion, a PE ratio of 41.89, a price-to-earnings-growth ratio of 2.10 and a beta of 1.17. The company’s 50-day moving average price is $69.66 and its two-hundred day moving average price is $93.70. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.